Symbols / VRPX $0.01 +1485.71% Virpax Pharmaceuticals, Inc.
VRPX Chart
About
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Stock Fundamentals
Scroll to Statements| Market Cap | 13.79K | Enterprise Value | -1.50M | Income | -12.07M | Sales | — | Book/sh | -1.53 | Cash/sh | 1.42 |
| Dividend Yield | — | Payout | 0.00% | Employees | 2 | IPO | — | P/E | — | Forward P/E | -0.01 |
| PEG | — | P/S | — | P/B | -0.01 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 0.61 | Current Ratio | 0.63 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -71.00 | EPS next Y | -0.90 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2025-03-03 | ROA | -135.01% | ROE | -23.65% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.24M | Shs Float | 1.05M | Short Float | 1.81% |
| Short Ratio | 0.04 | Short Interest | — | 52W High | 0.48 | 52W Low | 0.00 | Beta | 2.44 | Avg Volume | 333.00 |
| Volume | 51.00 | Target Price | — | Recom | None | Prev Close | $0.00 | Price | $0.01 | Change | 1485.71% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-177.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-09 | down | Maxim Group | Buy → Hold | — |
| 2024-07-19 | up | Maxim Group | Hold → Buy | $3 |
| 2024-05-22 | down | Maxim Group | Buy → Hold | — |
- Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com hu, 03 Apr 2025 07
- VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly - InvestorPlace Wed, 18 Aug 2021 07
- Latest VRPX News - Virpax Pharmaceuticals Announces Reverse St... - Stock Titan Wed, 17 Feb 2021 00
- Virpax Pharmaceuticals Stock Price Forecast. Should You Buy VRPX? - StockInvest.us Mon, 15 Mar 2021 16
- VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews Fri, 28 Feb 2025 08
- Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis - MarketBeat hu, 18 Feb 2021 00
- Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com hu, 03 Apr 2025 07
- These stocks have an unusual volume in today's session - ChartMill Wed, 10 Jul 2024 07
- Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today? - InvestorPlace Wed, 10 Jul 2024 07
- Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com Wed, 19 Mar 2025 07
- Which stocks have an unusual volume on Monday? - ChartMill Mon, 18 Dec 2023 08
- Virpax Pharmaceuticals, Inc. (VRPX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex hu, 30 Mar 2023 11
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
12.08
-28.69%
|
16.94
-22.46%
|
21.85
+81.66%
|
12.03
|
| Research And Development |
|
5.82
+13.71%
|
5.12
-52.45%
|
10.76
+122.41%
|
4.84
|
| Selling General And Administration |
|
6.26
-47.04%
|
11.82
+6.67%
|
11.08
+54.21%
|
7.19
|
| General And Administrative Expense |
|
6.26
-47.04%
|
11.82
+6.67%
|
11.08
+54.21%
|
7.19
|
| Salaries And Wages |
|
—
|
0.34
|
—
|
—
|
| Other Gand A |
|
6.26
-45.50%
|
11.49
+3.65%
|
11.08
+54.21%
|
7.19
|
| Total Expenses |
|
12.08
-28.69%
|
16.94
-22.46%
|
21.85
+81.66%
|
12.03
|
| Operating Income |
|
-12.08
+28.69%
|
-16.94
+22.46%
|
-21.85
-81.66%
|
-12.03
|
| Total Operating Income As Reported |
|
-12.08
+23.01%
|
-15.69
+28.18%
|
-21.85
-81.66%
|
-12.03
|
| EBITDA |
|
-11.96
+29.38%
|
-16.94
+22.46%
|
-21.85
-82.60%
|
-11.96
|
| Normalized EBITDA |
|
-11.96
+34.23%
|
-18.19
+16.73%
|
-21.85
-82.60%
|
-11.96
|
| EBIT |
|
-11.96
+29.38%
|
-16.94
+22.46%
|
-21.85
-82.60%
|
-11.96
|
| Total Unusual Items |
|
—
|
1.25
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
1.25
|
—
|
—
|
| Special Income Charges |
|
—
|
1.25
|
—
|
—
|
| Other Special Charges |
|
—
|
-1.25
|
—
|
—
|
| Net Income |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Pretax Income |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Net Non Operating Interest Income Expense |
|
-0.10
|
—
|
0.00
+100.00%
|
-0.09
|
| Interest Expense Non Operating |
|
0.10
|
—
|
0.00
-100.00%
|
0.09
|
| Net Interest Income |
|
-0.10
|
—
|
0.00
+100.00%
|
-0.09
|
| Interest Expense |
|
0.10
|
—
|
0.00
-100.00%
|
0.09
|
| Other Income Expense |
|
0.12
-93.35%
|
1.75
+800.29%
|
0.19
+212.26%
|
0.06
|
| Other Non Operating Income Expenses |
|
0.12
-76.72%
|
0.50
+157.33%
|
0.19
+212.26%
|
0.06
|
| Tax Provision |
|
—
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Net Income From Continuing And Discontinued Operation |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Net Income Continuous Operations |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Normalized Income |
|
-12.07
+26.60%
|
-16.44
+24.07%
|
-21.65
-79.58%
|
-12.06
|
| Net Income Common Stockholders |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Diluted EPS |
|
—
|
-324.25
+29.89%
|
-462.50
-2.21%
|
-452.50
|
| Basic EPS |
|
—
|
-324.25
+29.89%
|
-462.50
-2.21%
|
-452.50
|
| Basic Average Shares |
|
—
|
0.05
+0.00%
|
0.05
+75.40%
|
0.03
|
| Diluted Average Shares |
|
—
|
0.05
+0.00%
|
0.05
+75.40%
|
0.03
|
| Diluted NI Availto Com Stockholders |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1.56
-83.84%
|
9.63
-51.06%
|
19.67
-50.28%
|
39.57
|
| Current Assets |
|
1.56
-83.84%
|
9.63
-51.06%
|
19.67
-50.28%
|
39.57
|
| Cash Cash Equivalents And Short Term Investments |
|
1.51
-83.45%
|
9.14
-51.87%
|
19.00
-48.44%
|
36.84
|
| Cash And Cash Equivalents |
|
1.51
-83.45%
|
9.14
-51.87%
|
19.00
-48.44%
|
36.84
|
| Cash Financial |
|
1.51
-83.45%
|
9.14
-51.87%
|
19.00
-48.44%
|
36.84
|
| Prepaid Assets |
|
0.00
-98.89%
|
0.42
-35.74%
|
0.65
+155.24%
|
0.26
|
| Current Deferred Assets |
|
0.00
|
0.00
|
—
|
—
|
| Other Current Assets |
|
0.03
-48.18%
|
0.07
+165.27%
|
0.03
-98.98%
|
2.47
|
| Total Non Current Assets |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Non Current Deferred Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.47
-67.91%
|
7.69
+148.63%
|
3.09
+48.23%
|
2.09
|
| Current Liabilities |
|
2.47
-67.91%
|
7.69
+148.63%
|
3.09
+48.23%
|
2.09
|
| Payables And Accrued Expenses |
|
2.47
+45.77%
|
1.69
+54.76%
|
1.09
-47.57%
|
2.09
|
| Payables |
|
0.04
+122.44%
|
0.02
-50.97%
|
0.04
+89.73%
|
0.02
|
| Other Payable |
|
0.04
+122.44%
|
0.02
-50.97%
|
0.04
+89.73%
|
0.02
|
| Current Accrued Expenses |
|
2.43
+44.93%
|
1.68
+58.53%
|
1.06
-48.89%
|
2.07
|
| Total Tax Payable |
|
—
|
—
|
—
|
0.01
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Other Current Liabilities |
|
—
|
6.00
+200.00%
|
2.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Common Stock Equity |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Capital Stock |
|
0.00
+1141.67%
|
0.00
+0.00%
|
0.00
-89.74%
|
0.00
|
| Common Stock |
|
0.00
+1141.67%
|
0.00
+0.00%
|
0.00
-89.74%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
0.60
+1171.11%
|
0.05
-0.02%
|
0.05
0.00%
|
0.05
|
| Ordinary Shares Number |
|
0.60
+1171.11%
|
0.05
-0.02%
|
0.05
0.00%
|
0.05
|
| Additional Paid In Capital |
|
70.70
+15.00%
|
61.48
+0.89%
|
60.93
+1.24%
|
60.19
|
| Retained Earnings |
|
-71.61
-20.27%
|
-59.54
-34.25%
|
-44.35
-95.36%
|
-22.70
|
| Total Equity Gross Minority Interest |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Total Capitalization |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Working Capital |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Invested Capital |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Net Tangible Assets |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Tangible Book Value |
|
-0.91
-147.24%
|
1.93
-88.33%
|
16.58
-55.77%
|
37.48
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-16.71
-69.61%
|
-9.85
+44.79%
|
-17.85
-22.72%
|
-14.54
|
| Cash Flow From Continuing Operating Activities |
|
-16.71
-69.61%
|
-9.85
+44.79%
|
-17.85
-22.72%
|
-14.54
|
| Net Income From Continuing Operations |
|
-12.07
+20.56%
|
-15.19
+29.84%
|
-21.65
-79.58%
|
-12.06
|
| Stock Based Compensation |
|
0.13
-75.27%
|
0.54
-26.88%
|
0.75
-23.53%
|
0.97
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-0.06
|
| Change In Working Capital |
|
-4.78
-199.78%
|
4.79
+56.62%
|
3.06
+190.00%
|
-3.40
|
| Change In Prepaid Assets |
|
0.44
+131.96%
|
0.19
-90.67%
|
2.05
+175.66%
|
-2.71
|
| Change In Payables And Accrued Expense |
|
0.78
+29.35%
|
0.60
+160.36%
|
-0.99
-44.60%
|
-0.69
|
| Change In Payable |
|
—
|
—
|
—
|
-0.69
|
| Change In Account Payable |
|
—
|
—
|
—
|
-0.69
|
| Change In Other Current Liabilities |
|
-6.00
-250.00%
|
4.00
+100.00%
|
2.00
|
0.00
|
| Financing Cash Flow |
|
9.08
|
0.00
|
0.00
-100.00%
|
51.33
|
| Cash Flow From Continuing Financing Activities |
|
9.08
|
0.00
|
0.00
-100.00%
|
51.33
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-1.50
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-1.60
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.10
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
-1.60
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
-1.50
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-1.60
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-1.50
|
| Net Common Stock Issuance |
|
6.32
|
0.00
|
0.00
-100.00%
|
58.02
|
| Proceeds From Stock Option Exercised |
|
2.77
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-5.19
|
| Changes In Cash |
|
-7.63
+22.58%
|
-9.85
+44.79%
|
-17.85
-148.51%
|
36.79
|
| Beginning Cash Position |
|
9.14
-51.87%
|
19.00
-48.44%
|
36.84
+67134.82%
|
0.05
|
| End Cash Position |
|
1.51
-83.45%
|
9.14
-51.87%
|
19.00
-48.44%
|
36.84
|
| Free Cash Flow |
|
-16.71
-69.61%
|
-9.85
+44.79%
|
-17.85
-22.72%
|
-14.54
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.36
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Common Stock Issuance |
|
6.32
|
0.00
|
0.00
-100.00%
|
58.02
|
| Issuance Of Capital Stock |
|
6.32
|
0.00
|
0.00
-100.00%
|
58.02
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|